CMP ₹1,421 | Q4 PAT ₹2,619 Cr | EPS ₹37.11 | FY25 PAT ₹11,113 Cr | P/E ~12.8x | Dividend ₹2.5/share
📌 At a Glance:
Glenmark just posted jaw-dropping Q4 numbers, but before you start thinking “multibagger loading”, read the footnotes:
- Yes, Q4 PAT was ₹2,619 Cr ✅
- But ₹1,749 Cr was one-time exceptional charges
- Without the adjustment, profit is actually closer to ₹870 Cr
- FY25 EPS: ₹37.11
- CMP ₹1,421 ➝ P/E ~38x without adj., ~12.8x with adj.
- Final Dividend: ₹2.5 per share ✅
- Revenue Growth YoY: +12.7%
- Net Debt ✅ reduced by ~₹5,200 Cr post GLS exit
📊 Q4 FY25: Too Good To Be True?
| Metric | Q4 FY25 (₹ Cr) | Q3 FY25 (₹ Cr) | Q4 FY24 (₹ Cr) |
|---|
| Revenue | 3,388 | 3,202 | 3,016 |
| Reported PAT | 2,619 | 348 | 2,609 |
| Exceptional Item | ₹1,749 Cr (Loss) | None | ₹4,467 Cr (loss) |
| Adjusted PAT (Est.) | ~₹870 Cr | 348 | ~₹2,620 Cr (included GLS gain) |
| EPS (Reported) | ₹37.11 | ₹5.24 | ₹37.10 |
💥 YoY PAT appears flat only because last year had Glenmark Life Sciences sale profits.
🧾 This year’s spike? Reversal of prior
